Stocktoria
BioAtla, Inc. BCAB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-16
BioAtla, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $300,000 |
| R&D expense | $43.6M | $63.1M | $103.7M | $79.3M | $58.3M |
| Operating income | -$59.3M | -$73.9M | -$129.7M | -$108.1M | -$96.4M |
| Interest expense | — | — | — | $0 | $3,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.6M | -$69.8M | -$123.5M | -$106.5M | -$95.4M |
| EPS (diluted) | $-1.01 | $-1.44 | $-2.58 | $-2.74 | $-2.76 |
| Operating cash flow | -$48.2M | -$71.9M | -$104.0M | -$90.4M | -$62.2M |
| Cash & equivalents | $7.1M | $49.0M | $111.5M | $215.5M | $245.0M |
| Total assets | $13.8M | $52.4M | $119.7M | $225.7M | $254.4M |
| Total liabilities | $50.0M | $38.2M | $49.0M | $45.4M | $43.6M |
| Shareholders' equity | -$36.2M | $14.3M | $70.7M | $180.3M | $210.8M |
Source: SEC EDGAR filings · CIK 0001826892 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.